{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:00:39Z","timestamp":1792652439049,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41423-020-0417-8","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T13:04:12Z","timestamp":1587387852000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":182,"title":["Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics"],"prefix":"10.1038","volume":"17","author":[{"given":"Heliang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phei","family":"Er Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","volume":"26","author":"L Apetoh","year":"2015","unstructured":"Apetoh, L., Ladoire, S., Coukos, G. & Ghiringhelli, F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann. Oncol. 26, 1813\u20131823 (2015).","journal-title":"Ann. Oncol."},{"key":"417_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrd984","volume":"2","author":"OH Brekke","year":"2003","unstructured":"Brekke, O. H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52\u201362 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"417_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams, G. P. & Weiner, L. M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147\u20131157 (2005).","journal-title":"Nat. Biotechnol."},{"key":"417_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011\u20131027 (2005).","journal-title":"J. Clin. Oncol."},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ctrv.2015.10.008","volume":"41","author":"LM Henricks","year":"2015","unstructured":"Henricks, L. M., Schellens, J. H., Huitema, A. D. & Beijnen, J. H. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat. Rev. 41, 859\u2013867 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57\u201366 (2015).","journal-title":"Lancet Oncol."},{"key":"417_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S1470-2045(15)00039-X","volume":"16","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y., Choi, S. H. & Shah, K. Multifunctional receptor-targeting antibodies for cancer therapy. Lancet Oncol. 16, e543\u2013e554 (2015).","journal-title":"Lancet Oncol."},{"key":"417_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur, A., Huang, M. & Lum, L. G. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 32, 339\u2013347 (2018).","journal-title":"Blood Rev."},{"key":"417_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pharmthera.2017.12.002","volume":"185","author":"A Krishnamurthy","year":"2018","unstructured":"Krishnamurthy, A. & Jimeno, A. Bispecific antibodies for cancer therapy: a review. Pharm. Ther. 185, 122\u2013134 (2018).","journal-title":"Pharm. Ther."},{"key":"417_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","volume":"65","author":"A Viardot","year":"2018","unstructured":"Viardot, A. & Bargou, R. Bispecific antibodies in haematological malignancies. Cancer Treat. Rev. 65, 87\u201395 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","volume":"17","author":"KE Tiller","year":"2015","unstructured":"Tiller, K. E. & Tessier, P. M. Advances in antibody design. Annu. Rev. Biomed. Eng. 17, 191\u2013216 (2015).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","volume":"201","author":"FV Suurs","year":"2019","unstructured":"Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de Groot, D. J. A. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol. Ther. 201, 103\u2013119 (2019).","journal-title":"Pharmacol. Ther"},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann, R. E. & Brinkmann, U. Bispecific antibodies. Drug Discov. Today 20, 838\u2013847 (2015).","journal-title":"Drug Discov. Today"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tips.2016.09.005","volume":"37","author":"BV Ayyar","year":"2016","unstructured":"Ayyar, B. V., Arora, S. & O'Kennedy, R. Coming-of-age of antibodies in cancer therapeutics. Trends Pharm. Sci. 37, 1009\u20131028 (2016).","journal-title":"Trends Pharm. Sci."},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez, M. P., Bonifant, C. L. & Gottschalk, S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131, 30\u201338 (2018).","journal-title":"Blood"},{"key":"417_CR17","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22, 868\u2013876 (2011).","journal-title":"Curr. Opin. Biotechnol."},{"key":"417_CR18","first-page":"38","volume":"8","author":"H Liu","year":"2017","unstructured":"Liu, H., Saxena, A., Sidhu, S. S. & Wu, D. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front. Immunol. 8, 38 (2017).","journal-title":"Front. Immunol."},{"key":"417_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4236\/abb.2013.45090","volume":"4","author":"AP Herrington-Symes","year":"2013","unstructured":"Herrington-Symes, A. P., Farys, M., Khalili, H. & Brocchini, S. Antibody fragments: prolonging circulation half-life special issue-antibody research. Adv. Biosci. Biotechnol. 4, 689\u2013698 (2013).","journal-title":"Adv. Biosci. Biotechnol."},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"25612","DOI":"10.1074\/jbc.M109.027078","volume":"284","author":"R Stork","year":"2009","unstructured":"Stork, R., Campigna, E., Robert, B., Muller, D. & Kontermann, R. E. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J. Biol. Chem. 284, 25612\u201325619 (2009).","journal-title":"J. Biol. Chem."},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","volume":"93","author":"A Nisonoff","year":"1961","unstructured":"Nisonoff, A. & Rivers, M. M. Recombination of a mixture of univalent antibody fragments of different specificity. Arch. Biochem. Biophys. 93, 460\u2013462 (1961).","journal-title":"Arch. Biochem. Biophys."},{"key":"417_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495\u2013497 (1975).","journal-title":"Nature"},{"key":"417_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1126\/science.3925553","volume":"229","author":"M Brennan","year":"1985","unstructured":"Brennan, M., Davison, PF. & Paulus, H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229, 81\u201383 (1985).","journal-title":"Science"},{"key":"417_CR24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4049\/jimmunol.155.1.219","volume":"155","author":"H Lindhofer","year":"1995","unstructured":"Lindhofer, H., Mocikat, R., Steipe, B. & Thierfelder, S. Preferential species-restricted heavy\/light chain pairing in rat\/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155, 219\u2013225 (1995).","journal-title":"J. Immunol."},{"key":"417_CR25","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges, A. et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study. Clin. Cancer Res. 13, 3899\u20133905 (2007).","journal-title":"Clin. Cancer Res."},{"key":"417_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant, AM. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677\u2013681 (1998).","journal-title":"Nat. Biotechnol."},{"key":"417_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nrd4478","volume":"13","author":"K Garber","year":"2014","unstructured":"Garber, K. Bispecific antibodies rise again. Nat. Rev. Drug Discov. 13, 799\u2013801 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"417_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.biotechadv.2010.07.004","volume":"28","author":"J Pande","year":"2010","unstructured":"Pande, J., Szewczyk, M. M. & Grover, A. K. Phage display: concept, innovations, applications and future. Biotechnol. Adv. 28, 849\u2013858 (2010).","journal-title":"Biotechnol. Adv."},{"key":"417_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway, JB., Presta, LG. & Carter, P. \u2018Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617\u2013621 (1996).","journal-title":"Protein Eng."},{"key":"417_CR30","doi-asserted-by":"publisher","first-page":"19637","DOI":"10.1074\/jbc.M110.117382","volume":"285","author":"K Gunasekaran","year":"2010","unstructured":"Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637\u201319646 (2010).","journal-title":"J. Biol. Chem."},{"key":"417_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/jmbi.1997.1116","volume":"270","author":"S Atwell","year":"1997","unstructured":"Atwell, S., Ridgway, JB., Wells, JA. & Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270, 26\u201335 (1997).","journal-title":"J. Mol. Biol."},{"key":"417_CR32","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","volume":"108","author":"W Schaefer","year":"2011","unstructured":"Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl Acad. Sci. USA 108, 11187\u201311192 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"417_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"417_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nbt1345","volume":"25","author":"C Wu","year":"2007","unstructured":"Wu, C. et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25, 1290\u20131297 (2007).","journal-title":"Nat. Biotechnol."},{"key":"417_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/protein\/gzp077","volume":"23","author":"KD Orcutt","year":"2010","unstructured":"Orcutt, K. D. et al. A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel. 23, 221\u2013228 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"417_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cbpa.2013.04.015","volume":"17","author":"C Eigenbrot","year":"2013","unstructured":"Eigenbrot, C. & Fuh, G. Two-in-one antibodies with dual action Fabs. Curr. Opin. Chem. Biol. 17, 400\u2013405 (2013).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"417_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7113","volume":"6","author":"N Fischer","year":"2015","unstructured":"Fischer, N. et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat. Commun. 6, 6113 (2015).","journal-title":"Nat. Commun."},{"key":"417_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","volume":"8","author":"G Fan","year":"2015","unstructured":"Fan, G., Wang, Z., Hao, M. & Li, J. Bispecific antibodies and their applications. J. Hematol. Oncol. 8, 130 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"417_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","volume":"14","author":"R Ahamadi-Fesharaki","year":"2019","unstructured":"Ahamadi-Fesharaki, R. et al. Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow. Mol. Ther. Oncolytics 14, 38\u201356 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"417_CR40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","volume":"8","author":"P Bannas","year":"2017","unstructured":"Bannas, P., Hambach, J. & Koch-Nolte, F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front. Immunol. 8, 1603 (2017).","journal-title":"Front. Immunol."},{"key":"417_CR41","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpt.651","volume":"101","author":"T Yuraszeck","year":"2017","unstructured":"Yuraszeck, T., Kasichayanula, S. & Benjamin, J. E. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin. Pharm. Ther. 101, 634\u2013645 (2017).","journal-title":"Clin. Pharm. Ther."},{"key":"417_CR42","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035\u20134039 (2015).","journal-title":"Clin. Cancer Res."},{"key":"417_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/jmbi.1999.3156","volume":"293","author":"M Sergey","year":"1999","unstructured":"Sergey, M. et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293, 41\u201356 (1999).","journal-title":"J. Mol. Biol"},{"key":"417_CR44","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","volume":"117","author":"PA Moore","year":"2011","unstructured":"Moore, P. A. et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117, 4542\u20134551 (2011).","journal-title":"Blood"},{"key":"417_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. MAbs 9, 182\u2013212 (2017).","journal-title":"MAbs"},{"key":"417_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/0140-6736(90)90205-J","volume":"335","author":"T Nitta","year":"1990","unstructured":"Nitta, T., Stao, K., Yagita, H., Okumura, K. & Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335, 368\u2013376 (1990).","journal-title":"Lancet"},{"key":"417_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/BF01525390","volume":"40","author":"GCD Gast","year":"1995","unstructured":"Gast, G. C. D. et al. CD8 T cell activation after intravenous administration of CD3\u00d7CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 40, 390\u2013396 (1995).","journal-title":"Cancer Immunol. Immunother."},{"key":"417_CR48","first-page":"7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack, M., Riethm\u00fcller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Immunology 92, 7021\u20137025 (1995).","journal-title":"Immunology"},{"key":"417_CR49","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.V89.6.2042","volume":"89","author":"F Hartmann","year":"2019","unstructured":"Hartmann, F. et al. Treatment of refractory Hodgkin's disease with an anti-CD16 CD30 bispecific antibody. Blood 89, 2042\u20132047 (2019).","journal-title":"Blood"},{"key":"417_CR50","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler, A. et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098\u20132103 (2000).","journal-title":"Blood"},{"key":"417_CR51","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen, D., Kufer, P., Baeuerle, P. A. & Bargou, R. Blinatumomab: a historical perspective. Pharm. Ther. 136, 334\u2013342 (2012).","journal-title":"Pharm. Ther."},{"key":"417_CR52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974\u2013976 (2008).","journal-title":"Science"},{"key":"417_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","volume":"2","author":"R Linke","year":"2010","unstructured":"Linke, R., Klein, A. & Seimetz, D. Catumaxomab: clinical development and future directions. MAbs 2, 129\u2013136 (2010).","journal-title":"MAbs"},{"key":"417_CR54","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss, M. M. et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J. Cancer 127, 2209\u20132221 (2010).","journal-title":"Int J. Cancer"},{"key":"417_CR55","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41571-018-0087-y","volume":"15","author":"T Hilal","year":"2018","unstructured":"Hilal, T. & Prasad, V. Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. Nat. Rev. Clin. Oncol. 15, 727\u2013728 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"417_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez, MP., Bonifant, CL. & Gottschalk, S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131, 30\u201338 (2018).","journal-title":"Blood"},{"key":"417_CR57","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","volume":"5","author":"HJ Jackson","year":"2015","unstructured":"Jackson, H. J. & Brentjens, R. J. Overcoming antigen escape with CAR T-cell Therapy. Cancer Discov. 5, 1238\u20131240 (2015).","journal-title":"Cancer Discov."},{"key":"417_CR58","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"417_CR59","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.24571","volume":"92","author":"F Zaja","year":"2017","unstructured":"Zaja, F. et al. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? Am. J. Hematol. 92, E1\u2013E2 (2017).","journal-title":"Am. J. Hematol."},{"key":"417_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig, F. et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129, 100\u2013104 (2017).","journal-title":"Blood"},{"key":"417_CR61","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"417_CR62","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1021\/acs.molpharmaceut.5b00268","volume":"12","author":"N Dimasi","year":"2015","unstructured":"Dimasi, N. et al. Development of a trispecific antibody designed to simultaneously and efficiently target three different antigens on tumor cells. Mol. Pharm. 12, 3490\u20133501 (2015).","journal-title":"Mol. Pharm."},{"key":"417_CR63","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1365-2141.2010.08300.x","volume":"150","author":"M Kugler","year":"2010","unstructured":"Kugler, M. et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br. J. Haematol. 150, 574\u2013586 (2010).","journal-title":"Br. J. Haematol."},{"key":"417_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1158\/0008-5472.CAN-14-1670","volume":"75","author":"S Hu","year":"2015","unstructured":"Hu, S. et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER\/MET crosstalk. Cancer Res. 75, 159\u2013170 (2015).","journal-title":"Cancer Res."},{"key":"417_CR65","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nri2747","volume":"10","author":"A Beck","year":"2010","unstructured":"Beck, A., Wurch, T., Bailly, C. & Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10, 345\u2013352 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"417_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"N Ton","year":"2015","unstructured":"Ton, N. & Schumacher, R. D. S. Neoantigens in cancer immunotherapy. Science 348, 69\u201373 (2015).","journal-title":"Science"},{"key":"417_CR67","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Johnson, B. A. 3rd, Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209\u2013222 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"417_CR68","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cell.2017.01.014","volume":"168","author":"XS Liu","year":"2017","unstructured":"Liu, X. S. & Mardis, E. R. Applications of immunogenomics to cancer. Cell 168, 600\u2013612 (2017).","journal-title":"Cell"},{"key":"417_CR69","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature08250","volume":"461","author":"SB Ng","year":"2009","unstructured":"Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272\u2013276 (2009).","journal-title":"Nature"},{"key":"417_CR70","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","volume":"2","author":"EF Fritsch","year":"2014","unstructured":"Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522\u2013529 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"417_CR71","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"417_CR72","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.coph.2008.08.011","volume":"8","author":"DT Loo","year":"2008","unstructured":"Loo, D. T. & Mather, J. P. Antibody-based identification of cell surface antigens: targets for cancer therapy. Curr. Opin. Pharmacol. 8, 627\u2013631 (2008).","journal-title":"Curr. Opin. Pharmacol."},{"key":"417_CR73","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu Rev. Immunol."},{"key":"417_CR74","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1002\/anie.201710407","volume":"57","author":"M Konstantinidou","year":"2018","unstructured":"Konstantinidou, M., Zarganes-Tzitzikas, T., Magiera-Mularz, K., Holak, T. A. & Domling, A. Immune checkpoint PD-1\/PD-L1: is there life beyond antibodies? Angew. Chem. Int. Ed. Engl. 57, 4840\u20134848 (2018).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"417_CR75","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-15-3451","volume":"76","author":"M Hettich","year":"2016","unstructured":"Hettich, M., Lahoti, J., Prasad, S. & Niedermann, G. Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing gamma-Irradiation. Cancer Res. 76, 4673\u20134683 (2016).","journal-title":"Cancer Res."},{"key":"417_CR76","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27, 450\u2013461 (2015).","journal-title":"Cancer Cell."},{"key":"417_CR77","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2015","unstructured":"Krupka, C. et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 30, 484\u2013491 (2015).","journal-title":"Leukemia"},{"key":"417_CR78","doi-asserted-by":"publisher","first-page":"e1062969","DOI":"10.1080\/2162402X.2015.1062969","volume":"5","author":"J Schreiner","year":"2016","unstructured":"Schreiner, J. et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 5, e1062969 (2016).","journal-title":"Oncoimmunology"},{"key":"417_CR79","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-015-1671-y","volume":"64","author":"T Osada","year":"2015","unstructured":"Osada, T. et al. CEA\/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol. Immunother. 64, 677\u2013688 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"417_CR80","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-13-3622-T","volume":"74","author":"TT Junttila","year":"2014","unstructured":"Junttila, T. T. et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 74, 5561\u20135571 (2014).","journal-title":"Cancer Res."},{"key":"417_CR81","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/0008-5472.CAN-16-3431","volume":"77","author":"CH Chang","year":"2017","unstructured":"Chang, C. H. et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells. Cancer Res. 77, 5384\u20135394 (2017).","journal-title":"Cancer Res."},{"key":"417_CR82","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10637-018-0689-3","volume":"37","author":"W Hou","year":"2019","unstructured":"Hou, W. et al. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Investig. New Drugs 37, 876\u2013889 (2019).","journal-title":"Investig. New Drugs"},{"key":"417_CR83","doi-asserted-by":"publisher","first-page":"e1466016","DOI":"10.1080\/2162402X.2018.1466016","volume":"7","author":"I Koopmans","year":"2018","unstructured":"Koopmans, I. et al. A novel bispecific antibody for EGFR-directed blockade of the PD-1\/PD-L1 immune checkpoint. Oncoimmunology 7, e1466016 (2018).","journal-title":"Oncoimmunology"},{"key":"417_CR84","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.jid.2019.01.038","volume":"139","author":"I Koopmans","year":"2019","unstructured":"Koopmans, I. et al. Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade. J. Investig. Dermatol. 139, 2343\u20132351.e3 (2019).","journal-title":"J. Investig. Dermatol"},{"key":"417_CR85","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","volume":"132","author":"M Herrmann","year":"2018","unstructured":"Herrmann, M. et al. Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood 132, 2484\u20132494 (2018).","journal-title":"Blood"},{"key":"417_CR86","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/13543776.2019.1637422","volume":"29","author":"I Herrera-Camacho","year":"2019","unstructured":"Herrera-Camacho, I. et al. Cancer immunotherapy using anti-TIM3\/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert Opin. Ther. Pat. 29, 587\u2013593 (2019).","journal-title":"Expert Opin. Ther. Pat."},{"key":"417_CR87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","volume":"7","author":"AM Kvarnhammar","year":"2019","unstructured":"Kvarnhammar, A. M. et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J. Immunother. Cancer 7, 103 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"417_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1034\/j.1600-065X.2003.00009.x","volume":"192","author":"LJ Appleman","year":"2003","unstructured":"Appleman, L. J. & Boussiotis, V. A. T cell anergy and costimulation. Immunological Rev. 192, 161\u2013180 (2003).","journal-title":"Immunological Rev."},{"key":"417_CR89","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cellimm.2008.04.006","volume":"251","author":"H Guo","year":"2008","unstructured":"Guo, H. et al. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Cell Immunol. 251, 102\u2013108 (2008).","journal-title":"Cell Immunol."},{"key":"417_CR90","doi-asserted-by":"publisher","first-page":"e1471442","DOI":"10.1080\/2162402X.2018.1471442","volume":"7","author":"S Fellermeier-Kopf","year":"2018","unstructured":"Fellermeier-Kopf, S. et al. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. Oncoimmunology 7, e1471442 (2018).","journal-title":"Oncoimmunology"},{"key":"417_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/leu.2013.243","volume":"28","author":"C Arndt","year":"2014","unstructured":"Arndt, C. et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 28, 59\u201369 (2014).","journal-title":"Leukemia"},{"key":"417_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0347-2","volume":"12","author":"K Urbanska","year":"2014","unstructured":"Urbanska, K. et al. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J. Transl. Med. 12, 347 (2014).","journal-title":"J. Transl. Med."},{"key":"417_CR93","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat Biotechnol"},{"key":"417_CR94","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/19420862.2019.1596511","volume":"11","author":"D Darowski","year":"2019","unstructured":"Darowski, D., Kobold, S., Jost, C. & Klein, C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. MAbs 11, 621\u2013631 (2019).","journal-title":"MAbs"},{"key":"417_CR95","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fonc.2019.00176","volume":"9","author":"NG Minutolo","year":"2019","unstructured":"Minutolo, N. G., Hollander, E. E. & Powell, D. J. Jr. The emergence of universal immune receptor T cell therapy for cancer. Front. Oncol. 9, 176 (2019).","journal-title":"Front. Oncol."},{"key":"417_CR96","first-page":"1","volume":"11","author":"J Li","year":"2019","unstructured":"Li, J. et al. CD3 bispecific antibody\u2013induced cytokine release is dispensable for cytotoxic T cell activity. Sci. Transl. Med. 11, 1\u201312 (2019).","journal-title":"Sci. Transl. Med."},{"key":"417_CR97","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","volume":"16","author":"G Habif","year":"2019","unstructured":"Habif, G., Crinier, A., Andre, P., Vivier, E. & Narni-Mancinelli, E. Targeting natural killer cells in solid tumors. Cell Mol. Immunol. 16, 415\u2013422 (2019).","journal-title":"Cell Mol. Immunol."},{"key":"417_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","volume":"31","author":"F Fang","year":"2017","unstructured":"Fang, F., Xiao, W. & Tian, Z. NK cell-based immunotherapy for cancer. Semin. Immunol. 31, 37\u201354 (2017).","journal-title":"Semin. Immunol."},{"key":"417_CR99","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason, M. K. et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123, 3016\u20133026 (2014).","journal-title":"Blood"},{"key":"417_CR100","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","volume":"11","author":"JU Schmohl","year":"2016","unstructured":"Schmohl, J. U., Gleason, M. K., Dougherty, P. R., Miller, J. S. & Vallera, D. A. Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells. Target Oncol. 11, 353\u2013361 (2016).","journal-title":"Target Oncol."},{"key":"417_CR101","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/cbr.2012.1329","volume":"28","author":"DA Vallera","year":"2013","unstructured":"Vallera, D. A. et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biotherapy Radiopharmaceuticals 28, 274\u2013282 (2013).","journal-title":"Cancer Biotherapy Radiopharmaceuticals"},{"key":"417_CR102","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","volume":"11","author":"MK Gleason","year":"2012","unstructured":"Gleason, M. K. et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Therapeutics 11, 2674\u20132684 (2012).","journal-title":"Mol. Cancer Therapeutics"},{"key":"417_CR103","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","volume":"177","author":"L Gauthier","year":"2019","unstructured":"Gauthier, L. et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell 177, 1701\u20131713 e16 (2019).","journal-title":"Cell"},{"key":"417_CR104","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera, D. A. et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin. Cancer Res. 22, 3440\u20133450 (2016).","journal-title":"Clin. Cancer Res."},{"key":"417_CR105","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1172\/JCI129338","volume":"129","author":"JJ Hodgins","year":"2019","unstructured":"Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C. & Ardolino, M. Killers 2.0: NK cell therapies at the forefront of cancer control. J. Clin. Investig. 129, 3499\u20133510 (2019).","journal-title":"J. Clin. Investig."},{"key":"417_CR106","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani, K. & Rouce, R. H. The application of natural killer cell immunotherapy for the treatment of cancer. Front. Immunol. 6, 578 (2015).","journal-title":"Front. Immunol."},{"key":"417_CR107","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.seminoncol.2016.10.005","volume":"43","author":"C Grigg","year":"2016","unstructured":"Grigg, C. et al. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin. Oncol. 43, 638\u2013646 (2016).","journal-title":"Semin. Oncol."},{"key":"417_CR108","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler, S. E., Speranza, M. C., Cho, C. F. & Chiocca, E. A. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 3, 841\u2013849 (2017).","journal-title":"JAMA Oncol."},{"key":"417_CR109","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/mt.2013.240","volume":"22","author":"F Yu","year":"2014","unstructured":"Yu, F. et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol. Ther. 22, 102\u2013111 (2014).","journal-title":"Mol. Ther."},{"key":"417_CR110","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"77","author":"CA Fajardo","year":"2017","unstructured":"Fajardo, C. A. et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 77, 2052\u20132063 (2017).","journal-title":"Cancer Res."},{"key":"417_CR111","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","volume":"24","author":"T Speck","year":"2018","unstructured":"Speck, T. et al. Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin. Cancer Res. 24, 2128\u20132137 (2018).","journal-title":"Clin. Cancer Res."},{"key":"417_CR112","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.15252\/emmm.201707567","volume":"9","author":"JD Freedman","year":"2017","unstructured":"Freedman, J. D. et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol. Med. 9, 1067\u20131087 (2017).","journal-title":"EMBO Mol. Med."},{"key":"417_CR113","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","volume":"4","author":"A Dyer","year":"2017","unstructured":"Dyer, A. et al. Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators. Mol. Ther. Oncolytics 4, 18\u201330 (2017).","journal-title":"Mol. Ther. Oncolytics"},{"key":"417_CR114","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","volume":"5","author":"S Illingworth","year":"2017","unstructured":"Illingworth, S. et al. Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus. Mol. Ther. Oncolytics 5, 62\u201374 (2017).","journal-title":"Mol. Ther. Oncolytics"},{"key":"417_CR115","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-019-0505-4","volume":"7","author":"J de Sostoa","year":"2019","unstructured":"de Sostoa, J. et al. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J. Immunother. Cancer 7, 19 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"417_CR116","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","volume":"78","author":"JD Freedman","year":"2018","unstructured":"Freedman, J. D. et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 78, 6852\u20136865 (2018).","journal-title":"Cancer Res."},{"key":"417_CR117","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/sj.cgt.7701021","volume":"14","author":"M Compte","year":"2007","unstructured":"Compte, M. et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther. 14, 380\u2013388 (2007).","journal-title":"Cancer Gene Ther."},{"key":"417_CR118","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mt.2016.116","volume":"24","author":"CL Bonifant","year":"2016","unstructured":"Bonifant, C. L. et al. CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia. Mol. Ther. 24, 1615\u20131626 (2016).","journal-title":"Mol. Ther."},{"key":"417_CR119","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2014.156","volume":"23","author":"K Iwahori","year":"2015","unstructured":"Iwahori, K. et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol. Ther. 23, 171\u2013178 (2015).","journal-title":"Mol. Ther."},{"key":"417_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/srep27130","volume":"6","author":"MP Velasquez","year":"2016","unstructured":"Velasquez, M. P. et al. T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Sci. Rep. 6, 27130 (2016).","journal-title":"Sci. Rep."},{"key":"417_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.38","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J. 6, e430 (2016).","journal-title":"Blood Cancer J."},{"key":"417_CR122","first-page":"860","volume":"5","author":"MP Velasquez","year":"2017","unstructured":"Velasquez, M. P. et al. CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells. cancer. Immunol. Res. 5, 860\u2013870 (2017).","journal-title":"Immunol. Res."},{"key":"417_CR123","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/jnci\/djh299","volume":"96","author":"M Studeny","year":"2004","unstructured":"Studeny, M. et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl Cancer Inst. 96, 1593\u20131603 (2004).","journal-title":"J. Natl Cancer Inst."},{"key":"417_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.73","volume":"5","author":"R Aliperta","year":"2015","unstructured":"Aliperta, R. et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 5, e348 (2015).","journal-title":"Blood Cancer J."},{"key":"417_CR125","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","volume":"10","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan. J. Hematol. Oncol. 10, 56 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"417_CR126","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J. Hematol. Oncol. 12, 46 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"417_CR127","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1525-0016(03)00168-0","volume":"8","author":"Z-Y Chen","year":"2003","unstructured":"Chen, Z.-Y., He, C.-Y., Ehrhardt, A. & Kay, M. A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 8, 495\u2013500 (2003).","journal-title":"Mol. Ther."},{"key":"417_CR128","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/nbt.1708","volume":"28","author":"MA Kay","year":"2010","unstructured":"Kay, M. A., He, C. Y. & Chen, Z. Y. A robust system for production of minicircle DNA vectors. Nat. Biotechnol. 28, 1287\u20131289 (2010).","journal-title":"Nat. Biotechnol."},{"key":"417_CR129","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/hum.2016.122","volume":"28","author":"X Pang","year":"2017","unstructured":"Pang, X. et al. Treatment of human B-cell lymphomas using minicircle DNA vector expressing Anti-CD3\/CD20 in a mouse model. Hum. Gene Ther. 28, 216\u2013225 (2017).","journal-title":"Hum. Gene Ther."},{"key":"417_CR130","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the \u2018high-hanging fruit'. Nat. Rev. Drug Discov. 17, 197\u2013223 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"417_CR131","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","volume":"122","author":"Z Elgundi","year":"2017","unstructured":"Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V. & Kayser, V. The state-of-play and future of antibody therapeutics. Adv. Drug Deliv. Rev. 122, 2\u201319 (2017).","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0417-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T06:39:43Z","timestamp":1672727983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0417-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-0417-8","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}